MayaHrachovaDO
Neurology • Oklahoma City, OKNeurooncology
Assistant Professor of Neuro-Oncology/ Medical Director Neuro-Oncology/ OU Health Stephenson Cancer Center
Dr. Hrachova is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
800 NE 10th Street. 6th Floor
Oklahoma City, OK 73104- Is this information wrong?
Summary
- Dr. Maya Hrachova is a board-certified neurologist and neuro-oncologist who specializes in the diagnosis and treatment of primary brain and spinal cord tumors, primary central nervous system lymphoma, brain metastases, neurofibromatosis and neurological complications of cancer.
Education & Training
Mayo Clinic HospitalNeuro-Oncology, 2020 - 2021
University of California (Irvine)Residency, Neurology, 2017 - 2020- University of California (Irvine)Internship, Internal Medicine, 2016 - 2017
College of Osteopathic Medicine of the PacificClass of 2016
Certifications & Licensure
CA State License 2018 - 2025
AZ State License 2020 - 2025
MN State License 2021 - 2024
OK State License 2021 - 2024- American Board of Psychiatry and Neurology Neurology
- United Council for Neurological Subspecialties Neuro-Oncology
Publications & Presentations
PubMed
- Evaluating the Patient with Neurotoxicity after Chimeric Antigen Receptor T-cell Therapy.Fortin Ensign SP, Gaulin C, Hrachova M, Ruff M, Harahsheh E, Vicenti K, Castro J, Munoz J, Rosenthal A, Mrugala MM> ;Current treatment options in oncology. 2022-12-16
- 4 citationsSomatostatin analogues in treatment-refractory meningioma: a systematic review with meta-analysis of individual patient data.Jensen, L., Maier, A., Lomstein, A., Graillon, T., Hrachova, M., Bota, D., Ruiz-Patiño, A., Arrieta, O., Cardona, A., Rudà, R., Furtner, J., Roeckle, U., Clement, P., ...> ;Neurosurgical Review. 2022 Oct 1
- 8 citationsPrognostic Implication of Patient Age in H3K27M-Mutant Midline Gliomas.Huy Gia Vuong, Tam N M Ngo, Hieu Trong Le, Andrew Jea, Maya Hrachova, James Battiste, Rene McNall-Knapp, Ian F Dunn> ;Frontiers in Oncology. 2022 Jan 1
- Join now to see all
Hospital Affiliations
OU HealthOklahoma City, Oklahoma
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
